Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes a multi-year strategic research collaboration announced in 2022 between Insilico Medicine and Sanofi, under which Sanofi uses Insilico's Pharma.AI platform to pursue drug candidates against up to six novel targets. Total deal value is stated as approximately $1.2 billion, with a $21.5 million upfront payment.

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.